Topic

All

27
Mar
2025

A Moment of Peril and Promise

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Mar
2025

NIH Cuts Threaten to Cede U.S. Life Science Dominance to China

The current debate over capping federal research overhead rates misses the forest for the trees. Federal investments in medical research have built a thriving U.S. biotech sector that employs 2.3 million people. Funding from the National Institutes of Health (NIH) provides the foundation for this success, supporting universities and research institutions that attract top scientists and foster innovation. The Trump...
Read More
23
Mar
2025

How a Dark Horse Candidate is Upending the Sequencing Market

Before Roche officially announced their new sequencer in a pre-AGBT webinar in February 2025, only true sequencing aficionados had heard of Stratos Genomics or Sequencing by Expansion (SBX). The SBX chemistry underlying Roche’s new sequencer was developed by Stratos Genomics, which Roche acquired in 2020 and paired with nanopore sensors from Genia Technologies, which Roche acquired way back in 2014....
Read More
18
Mar
2025

See the Photos from TR10 West

Thanks to everyone who attended the TR10 anniversary party Mar. 13 at Adaptive Biotechnologies. The toasts and roasts were funny, perceptive and heartfelt. It was a joyous occasion. Enjoy a few photos. Click to enlarge. Photos by Robert Wade.
18
Mar
2025

See the Photos from TR10 East

Thanks to everyone who attended the TR10 anniversary party Mar. 6 at Alnylam Pharmaceuticals. The toasts and roasts were funny, perceptive and heartfelt. There was a joyful community spirit in the room. Enjoy a few photos. Click to enlarge. Photos by Mike Mejia.
17
Mar
2025

Why Cell & Gene Therapy Companies Should Talk with RFK Jr.

As the CEO of the cell and gene therapy advocacy organization the Alliance for Regenerative Medicine (ARM), I’ve been asked one question more than any other amid the constant barrage of news headlines the past two months. How are you approaching the Trump Administration? I hear it from across our community, including biotechnology companies, academic and medical research institutions, patient...
Read More
11
Mar
2025

NIH Cuts Hit Young Scientists the Hardest

[Editor’s note: David Baker gave this speech to Seattle community leaders Mar. 10, at a celebration of his 2024 Nobel Prize in Chemistry.] Let me just briefly tell you how innovation arises in biomedicine and where drug discoveries come from. A large percentage of the innovation is made at universities by graduate students and postdocs. Often, they take their ideas...
Read More
9
Mar
2025

Scientists Standing Up in Seattle

Several thousand scientists gathered Friday in Seattle for one of the nationwide “Stand Up for Science” protests. People studying a range of disciplines — biology, climate change, public health and more — took a break from the lab to protest cuts to federal spending on science and mass firings. Morale had been low for weeks among many attendees, but Friday...
Read More
5
Mar
2025

Sluggish Corporate AI Adoption Has Motivated Entrepreneurs To Pick Their Spots 

As economic historian Carlota Perez has described, there is typically a significant time lag between when the promise of novel technology begins to emerge and the productive deployment of this technology at scale; TR readers will recall the discussion here from June 2023. Today, we are seeing this with generative AI, an emerging technology that everyone is still trying to...
Read More
4
Mar
2025

Flashback: Q&A on Founding TR

[Dear Readers: This Q&A from the Knight Science Journalism at MIT blog on Feb. 3, 2015 captures my thoughts on founding TR and where biotech was going. Thank you for your support. — Luke ] By Wade Roush For writers, part of the fuss about the Web explosion of the late 1990s was that it was finally possible to cut...
Read More